Literature DB >> 786355

Hepatic drug-oxidizing enzyme systems and urinary D-glucaric acid excretion in patients with congestive heart failure.

O Tokola, O Pelkonen, N T Karki, P Luoma.   

Abstract

Drug-oxidizing enzyme systems in liver biopsy samples and the urinary excretion of D-glucaric acid were studied in two different groups of patients with cardiac insufficiency. 2. In one group of six patients, the activities of drug-metabolizing enzymes had decreased considerably as compared with the control values, but in four liver samples from patients treated with oral hypoglycaemic agents for their diabetes, activities were higher than in control samples from ten patients. 3. In the other group of seven patients, the urinary excretion of D-glucaric acid (isolated by ion-exchange chromatography) was 60% lower than in the control group of nine humans, whereas in four patients taking antiepileptic agents excretion rate was higher than control values. 4. Because the age distribution was markedly different between cardiac insufficiency and control groups, it is difficult to conclude, if the impairment of drug metabolism was a consequence of the old age or of the disease process. However, drug-oxidizing enzyme systems seem to be inducible also in old age. 5. The results support further the opinion that the urinary excretion of D-glucaric acid may be one useful index in assessing an individual's capacity to metabolize foreign compounds especially in the patients with lowered drug metabolizing capacity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 786355      PMCID: PMC1402618          DOI: 10.1111/j.1365-2125.1975.tb00552.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes.

Authors:  S M RICHMAN; A J DELMAN; D GROB
Journal:  Am J Med       Date:  1961-02       Impact factor: 4.965

3.  Metabolism of d-glucuronolactone in mammalian systems. Identification of d-glucaric acid as a normal constituent of urine.

Authors:  C A Marsh
Journal:  Biochem J       Date:  1963-01       Impact factor: 3.857

4.  Changes in D-glucaric acid excretion in relationship to alterations in the rate of antipyrine metabolism in man.

Authors:  J Hunter; W R Burnham; L F Chasseaud; W Down
Journal:  Biochem Pharmacol       Date:  1974-09-01       Impact factor: 5.858

5.  Urinary D-glucaric acid excretion and acetanilide pharmacokinetics before and during diphenylhydantoin administration.

Authors:  J L Cunningham; D A Evans
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

6.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

Authors:  P D Thomson; K L Melmon; J A Richardson; K Cohn; W Steinbrunn; R Cudihee; M Rowland
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

7.  Rate of aminopyrine disappearance from plasma in young and aged humans.

Authors:  A Jori; E Di Salle; A Quadri
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

8.  Developmental effects on liver D-glucuronolactone dehydrogenase levels and on D-glucaric acid excretion in urine; hormonal effects on D-glucaric acid excretion in urine.

Authors:  A P Mowat
Journal:  J Endocrinol       Date:  1968-12       Impact factor: 4.286

9.  Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man.

Authors:  R E Stenson; R T Constantino; D C Harrison
Journal:  Circulation       Date:  1971-02       Impact factor: 29.690

10.  Effect of age and sex on human drug metabolism.

Authors:  K O'Malley; J Crooks; E Duke; I H Stevenson
Journal:  Br Med J       Date:  1971-09-11
View more
  7 in total

1.  Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.

Authors:  L F Prescott; K K Adjepon-Yamoah; R G Talbot
Journal:  Br Med J       Date:  1976-04-17

Review 2.  The elderly patient. A special case for diuretic therapy.

Authors:  D E Hyams
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

Review 4.  Pharmacokinetics in patients with cardiac failure.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

5.  Lignocaine and indocyanine green kinetics in patients following myocardial infarction.

Authors:  N D Bax; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

6.  Pharmacokinetics of oral hydralazine in chronic heart failure.

Authors:  A Hanson; B W Johansson; B Wernersson; L A Wåhlander
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Development of a gas chromatography-mass spectrometry method for the quantification of glucaric Acid derivatives in beverage substrates.

Authors:  Ana Paula Craig; Christine C Fields; John V Simpson
Journal:  Int J Anal Chem       Date:  2014-06-15       Impact factor: 1.885

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.